Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KTd versus KRd induction with carfilzomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
2016-000475-24Phase 2Completed
- Sponsor
- AGMT
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of carfilzomib, thalidomide, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by AGMT. Primary endpoint: Overall response rate after 9 cycles of induction. Started Jul 2016; status: completed.
02
Drugs
carfilzomibthalidomidelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2016-000475-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000475-24.